4/16
11:52 am
gmab
Should Value Investors Buy Genmab (GMAB) Stock? [Yahoo! Finance]
Low
Report
Should Value Investors Buy Genmab (GMAB) Stock? [Yahoo! Finance]
4/15
07:39 am
gmab
Genmab's Outlook Beyond Darzalex's Patent Cliff [Seeking Alpha]
Low
Report
Genmab's Outlook Beyond Darzalex's Patent Cliff [Seeking Alpha]
4/15
06:21 am
gmab
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2025
Low
Report
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2025
4/10
12:57 pm
gmab
Genmab A/S Share Capital Reduction [Yahoo! Finance]
Low
Report
Genmab A/S Share Capital Reduction [Yahoo! Finance]
4/9
08:10 am
gmab
Genmab A/S (NASDAQ: GMAB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $37.00 price target on the stock, down previously from $50.00.
Medium
Report
Genmab A/S (NASDAQ: GMAB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $37.00 price target on the stock, down previously from $50.00.
4/7
07:59 am
gmab
Transactions In Connection with Share Buy-back Program [Yahoo! Finance]
Medium
Report
Transactions In Connection with Share Buy-back Program [Yahoo! Finance]
4/4
08:30 am
gmab
New Chromatography Data Platform Wins Bio-IT World Award for Genmab and Genedata
Low
Report
New Chromatography Data Platform Wins Bio-IT World Award for Genmab and Genedata
4/2
10:11 am
gmab
Is Genmab A/S (GMAB) d The Most Profitable Biotech Stock To Buy Right Now? [Yahoo! Finance]
Low
Report
Is Genmab A/S (GMAB) d The Most Profitable Biotech Stock To Buy Right Now? [Yahoo! Finance]
4/1
09:04 am
gmab
Genmab A/S (NASDAQ: GMAB) was downgraded by analysts at Sanford C. Bernstein from a "market perform" rating to an "underperform" rating.
Low
Report
Genmab A/S (NASDAQ: GMAB) was downgraded by analysts at Sanford C. Bernstein from a "market perform" rating to an "underperform" rating.
3/31
11:33 am
gmab
TIVDAK® (tisotumab vedotin) Approved by European Commission for Previously Treated Recurrent or Metastatic Cervical Cancer [Yahoo! Finance]
Low
Report
TIVDAK® (tisotumab vedotin) Approved by European Commission for Previously Treated Recurrent or Metastatic Cervical Cancer [Yahoo! Finance]
3/31
11:20 am
gmab
TIVDAK® (tisotumab vedotin) Approved by European Commission for Previously Treated Recurrent or Metastatic Cervical Cancer
Low
Report
TIVDAK® (tisotumab vedotin) Approved by European Commission for Previously Treated Recurrent or Metastatic Cervical Cancer
3/31
09:03 am
gmab
This drug company's silver bullet is currently valued at zero [Yahoo! Finance]
Low
Report
This drug company's silver bullet is currently valued at zero [Yahoo! Finance]
3/27
08:00 am
gmab
TIVDAK® (tisotumab vedotin) Approved by Japan Ministry of Health, Labour and Welfare for the Treatment of Advanced or Recurrent Cervical Cancer that has Progressed on or after Chemotherapy
Low
Report
TIVDAK® (tisotumab vedotin) Approved by Japan Ministry of Health, Labour and Welfare for the Treatment of Advanced or Recurrent Cervical Cancer that has Progressed on or after Chemotherapy
3/24
10:30 am
gmab
Genmab A/S (GMAB): A Bull Case Theory [Yahoo! Finance]
Low
Report
Genmab A/S (GMAB): A Bull Case Theory [Yahoo! Finance]
3/21
11:28 pm
gmab
Genmab to Vigorously Defend Alleged Claims of Trade Secret Misappropriation by AbbVie Inc.
Medium
Report
Genmab to Vigorously Defend Alleged Claims of Trade Secret Misappropriation by AbbVie Inc.
3/17
12:45 pm
gmab
Investigational Rinatabart Sesutecan (Rina-S®) Continues to Show Encouraging Antitumor Activity in Patients with Advanced Ovarian Cancer [Yahoo! Finance]
Low
Report
Investigational Rinatabart Sesutecan (Rina-S®) Continues to Show Encouraging Antitumor Activity in Patients with Advanced Ovarian Cancer [Yahoo! Finance]
3/17
12:19 pm
gmab
Investigational Rinatabart Sesutecan (Rina-S®) Continues to Show Encouraging Antitumor Activity in Patients with Advanced Ovarian Cancer
Low
Report
Investigational Rinatabart Sesutecan (Rina-S®) Continues to Show Encouraging Antitumor Activity in Patients with Advanced Ovarian Cancer
3/11
12:53 pm
gmab
Genmab A/S (NASDAQ: GMAB) had its price target lowered by analysts at Truist Financial Co. from $50.00 to $45.00. They now have a "buy" rating on the stock.
Low
Report
Genmab A/S (NASDAQ: GMAB) had its price target lowered by analysts at Truist Financial Co. from $50.00 to $45.00. They now have a "buy" rating on the stock.
3/11
08:09 am
gmab
Genmab A/S (NASDAQ: GMAB) was upgraded by analysts at William Blair from a "market perform" rating to an "outperform" rating.
Medium
Report
Genmab A/S (NASDAQ: GMAB) was upgraded by analysts at William Blair from a "market perform" rating to an "outperform" rating.
3/10
10:21 am
gmab
Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38
Low
Report
Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38
3/10
10:13 am
gmab
Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38
Medium
Report
Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38
3/10
04:26 am
gmab
Lundbeck's potential treatment for Multiple System Atrophy granted Orphan Drug Designation in Japan [Yahoo! Finance]
Medium
Report
Lundbeck's potential treatment for Multiple System Atrophy granted Orphan Drug Designation in Japan [Yahoo! Finance]
2/20
08:51 am
gmab
EPKINLY® (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare for Additional Indication as a Treatment for Relapsed or Refractory Follicular Lymphoma [Yahoo! Finance]
Low
Report
EPKINLY® (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare for Additional Indication as a Treatment for Relapsed or Refractory Follicular Lymphoma [Yahoo! Finance]
2/20
08:00 am
gmab
EPKINLY® (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare for Additional Indication as a Treatment for Relapsed or Refractory Follicular Lymphoma
Low
Report
EPKINLY® (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare for Additional Indication as a Treatment for Relapsed or Refractory Follicular Lymphoma
2/18
10:37 am
gmab
Bispecific Antibody Market Expands with Over 600 Clinical Trials – New Patent Analysis Report Released [Yahoo! Finance]
Low
Report
Bispecific Antibody Market Expands with Over 600 Clinical Trials – New Patent Analysis Report Released [Yahoo! Finance]